Navigation Links
Satyam Posts 28 Percent Year-over-Year Revenue Growth in Second Quarter Despite Slowdown in Key Markets
Date:10/17/2008

HYDERABAD, India, Oct. 17 /PRNewswire-FirstCall/ -- Satyam Computer Services Ltd. (NYSE: SAY), a leading global consulting and information technology services company, today reported US GAAP results for its second quarter, which ended September 30, 2008.

Financial highlights

Despite a challenging market that impacted several key industries and regions, Satyam posted strong growth figures, and exceeded its guidance in the second quarter. Revenue was US$652.2 million, an increase of 28 percent year over year, and 2.3 percent sequentially. Net income was US$132.3 million, an increase of 29.8 percent year over year and 4.5 percent sequentially. In addition, basic earnings per ADS for the quarter was US$0.39, an increase of 25.8 percent year over year and 2.6 percent sequentially. Further, operating margin (earnings before interest and taxes) for the quarter was 20.3 percent.

"The second quarter was challenging in many respects, as problems in the US financial industry affected other regions and sectors," said Satyam Chairman and Founder B. Ramalinga Raju. "Despite this background, a heightened focus on operational efficiency, a comprehensive services portfolio and an ability to provide true transformation have enabled Satyam to excel."

Other highlights

The parent company ended the quarter with 48,434 Associates, an addition of 1,814 professionals, including 221 trainees. The total number of employees including subsidiaries and joint ventures is 52,865. Attrition, on a trailing 12-month basis, fell to 12.3 percent from 12.6 percent in Q1. Annualized attrition for the quarter stood at 12.7 percent, one of the lowest in the industry. In addition, Satyam added 33 new customers in the quarter.

Business Outl
'/>"/>

SOURCE Satyam Computer Services Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Satyam Launches Comprehensive, Mobile Healthcare Program for Rural Indians
2. GE and Satyam Announce Global Alliance to Provide Healthcare IT Services
3. Solos Endoscopy, Inc. Posts First Six Months Financials of 2008 on Pinksheets.com
4. Averting postsurgical infections in kids: Give antibiotics within hour before first incision
5. FinCor Holdings Posts Strong Fourth Quarter and Year-End Results
6. TeamStaff Reports Fourth Quarter and Fiscal 2007 Results; Posts Fourth Quarter Income From Operations
7. Irell & Manella Posts Strong Year for Corporate Transactions
8. FinCor Holdings Posts Double-Digit Increases in Revenue and Net Income for Third Quarter
9. Death rate 70 percent lower at top-rated hospitals: HealthGrades annual hospital quality study
10. Chilis Grill & Bar(R) to Donate 100 Percent of All Profits on Monday, Sept. 29 to St. Jude Childrens Research Hospital as Part of Annual Create-A-Pepper to Fight Childhood Cancer Campaign
11. Yearly Premiums for Family Health Coverage Rise to $12,680 in 2008, Up 5 Percent, As Many Workers Also Face Higher Deductibles
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 1The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 2The American Academy of Pediatrics Names Lu Ann Papile M D FAAP as Chair of the Fetus and Newborn Committee 50871 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 1Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 2Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 3Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 4Nutrition 21 Launches New Innovative PRESCRIPTIX 28TM 29 Nutraceuticals Product Line 50867 5AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 1AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 2AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 3AEterna Zentaris 3A New Data Published on its Ghrelin Antagonist Compound AEZS 123 28JMV2959 29 Supports its Use in Alcohol Addiction 12909 4